Page last updated: 2024-10-25

deferoxamine and Dysarthosis

deferoxamine has been researched along with Dysarthosis in 2 studies

Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yong, RL1
Holmes, DT1
Sreenivasan, GM1
Pogglitsch, H1
Petek, W1
Wawschinek, O1
Holzer, W1

Other Studies

2 other studies available for deferoxamine and Dysarthosis

ArticleYear
Aluminum toxicity due to intravenous injection of boiled methadone.
    The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11

    Topics: Adult; Aluminum; Ataxia; Chelation Therapy; Deferoxamine; Dysarthria; Humans; Male; Methadone; Poiso

2006
Treatment of early stages of dialysis encephalopathy by aluminium depletion.
    Lancet (London, England), 1981, Dec-12, Volume: 2, Issue:8259

    Topics: Aluminum; Apraxias; Brain Diseases; Deferoxamine; Dysarthria; Humans; Male; Renal Dialysis

1981